HeartBeam Inc. (NASDAQ: BEAT), a medical technology company focused on cardiac care, announced it will host a conference call on Aug. 13 at 4:30 p.m. ET to discuss financial results for the second quarter ended June 30, 2026, and provide updates on its strategy to accelerate global adoption of its ambulatory ECG signal platform. The call will be led by Executive Chairman Richard Ferrari, President and Founder Branislav Vajdic, and Chief Financial Officer Timothy Cruickshank, and will include a question-and-answer session following prepared remarks.
The announcement comes as HeartBeam continues to advance its proprietary 3D ECG technology, which the company describes as the first cable-free device capable of collecting ECG signals in three non-coplanar directions and synthesizing them into a 12-lead ECG. This platform is designed for portable use, enabling physicians to detect cardiac health trends and acute conditions outside of medical facilities. The company's technology received FDA clearance for arrhythmia assessment in December 2024 and for 12-lead ECG synthesis software in December 2025. HeartBeam holds over 20 issued patents related to its technology.
The upcoming call is significant for investors and the cardiac care industry, as it will provide insight into HeartBeam's commercialization strategy and financial health. The company's platform has the potential to redefine cardiac health management by allowing continuous monitoring and early detection of critical conditions, potentially reducing hospital visits and improving patient outcomes. For more details on the cleared indications for use, refer to HeartBeam's Indications for Use.
As HeartBeam seeks to expand its global footprint, the Q2 results will be closely watched for revenue growth, R&D spending, and progress toward regulatory approvals in international markets. The company's ability to scale production and secure partnerships will be key factors in its success. The full press release is available at https://ibn.fm/sqGLs. For the latest news and updates on HeartBeam, visit the company's newsroom at https://ibn.fm/BEAT.
Investors and industry analysts will be listening for details on how HeartBeam plans to differentiate its 3D ECG platform from traditional Holter monitors and other ambulatory ECG devices. The company's technology offers a unique value proposition by providing 12-lead ECG quality from a compact, cable-free device, which could improve patient compliance and diagnostic accuracy. The conference call will also address potential challenges, including competition from established medical device companies and the need for physician education.
The importance of this news lies in HeartBeam's potential to transform cardiac care by enabling remote monitoring and early intervention. With cardiovascular disease remaining a leading cause of death globally, innovations like HeartBeam's platform could have a profound impact on public health. The company's progress in securing FDA clearances and building its patent portfolio underscores its commitment to advancing cardiac diagnostics.
